Skip to content

The ROI of Generative AI

Generative AI continues to capture the imagination of business leaders, but is it truly paying off? As early adopters report significant gains, many organizations remain stuck in pilot mode or struggle to quantify results.

Measuring ROI from genAI is inherently complex. Still, a growing number of companies are beginning to track the financial impact of genAI, and success patterns are starting to emerge.

In this report, discover:

  • The current state of genAI ROI across industries
  • The cross-industry use cases delivering the most consistent returns
  • The strategic behaviors that set genAI leaders apart
  • What to expect going forward as costs fall and tools evolve

Explore more

Enterprise Software: Assessing AI Adoption Trends

Generative AI is moving from isolated pilots to full-scale deployments, with adoption accelerating in areas like software development and IT service management.
Title slide: Enterprise Software: Assessing AI Adoption Trends, by Michelle Brophy and Sean Carmichael, featuring a computer illustration and AI logo.

From Promise to Performance: How AI Will Evolve in 2026

2025 was the year generative AI grew up, shifting from isolated experiments to integrated systems. What also emerged was a clearer picture of how AI will continue to mature in 2026.
Title slide: From Promise to Performance: How AI Will Evolve in 2026 by Sarah Hoffman, Director of AI Thought Leadership, with abstract tech graphics.

Most-Favored-Nation Policy: Implications for European Drug Launches

The U.S. shift toward most-favored-nation (MFN) drug pricing is forcing pharmaceutical firms to rethink their pricing models and launch strategies in Europe.
U.S. Most-Favored-Nation Drug Pricing Policy: What Does It Mean for Europe? by Sara Mallatt and Sean Carmichael, with a stylized map of Europe.

Transform intelligence
into advantage

Develop bold strategies, seize opportunities,
and lead with clarity and confidence.